ArticleCancers2022

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.

Margarita Romeo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.